Takeda Announces FDA Approval Of HYQVIA For CIDP : vimarsana

Takeda (TAK) announced the FDA has approved HYQVIA for the treatment of chronic inflammatory demyelinating polyneuropathy as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

Related Keywords

Giles Platford , More Such Health News , Plasma Derived Therapies Business , Fda , Makeda , Yqvia ,